NASDAQ:PMN ProMIS Neurosciences (PMN) Stock Price, News & Analysis $1.60 -0.42 (-20.79%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.35▼$2.0550-Day Range$1.50▼$2.2752-Week Range$0.95▼$3.73Volume6.64 million shsAverage Volume71,424 shsMarket Capitalization$30.34 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get ProMIS Neurosciences alerts: Email Address ProMIS Neurosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside400.0% Upside$8.00 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.11) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.31 out of 5 starsMedical Sector605th out of 936 stocksPharmaceutical Preparations Industry278th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingProMIS Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProMIS Neurosciences has received no research coverage in the past 90 days.Read more about ProMIS Neurosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.18% of the float of ProMIS Neurosciences has been sold short.Short Interest Ratio / Days to CoverProMIS Neurosciences has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProMIS Neurosciences has recently increased by 72.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProMIS Neurosciences does not currently pay a dividend.Dividend GrowthProMIS Neurosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMN. Previous Next 2.9 News and Social Media Coverage News SentimentProMIS Neurosciences has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ProMIS Neurosciences this week, compared to 0 articles on an average week.Search Interest3 people have searched for PMN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added ProMIS Neurosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProMIS Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.39% of the stock of ProMIS Neurosciences is held by insiders.Percentage Held by Institutions50.13% of the stock of ProMIS Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProMIS Neurosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ProMIS Neurosciences are expected to grow in the coming year, from ($1.11) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProMIS Neurosciences is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProMIS Neurosciences is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProMIS Neurosciences has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ProMIS Neurosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.Click here and I’ll show you how to build the ultimate dividend portfolio. About ProMIS Neurosciences Stock (NASDAQ:PMN)ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More PMN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMN Stock News HeadlinesJuly 26 at 7:17 PM | msn.comWestwood and Majesticks aiming to dig deeper as LIV Golf heads to JCB ClubJuly 26 at 8:35 AM | globenewswire.comProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's TrialJuly 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 26 at 8:30 AM | globenewswire.comProMIS Neurosciences Announces Up to $122.7 Million Private Placement FinancingMay 15, 2024 | msn.comPMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024May 14, 2024 | globenewswire.comProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent HighlightsApril 30, 2024 | globenewswire.comProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed AntibodiesApril 17, 2024 | msn.comProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93July 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.April 9, 2024 | globenewswire.comProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSApril 4, 2024 | globenewswire.comProMIS Neurosciences to Present in Upcoming Investor Conferences in AprilApril 1, 2024 | globenewswire.comProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsMarch 11, 2024 | globenewswire.comProMIS Neurosciences Strengthens Global Intellectual Property PortfolioFebruary 22, 2024 | globenewswire.comProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceJanuary 22, 2024 | finance.yahoo.comProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein VaccineJanuary 3, 2024 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership TransitionJanuary 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)January 3, 2024 | markets.businessinsider.comProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive OfficerSee More Headlines Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMN CUSIPN/A CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+400.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,311.60% Return on Assets-130.13% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.34 Sales & Book Value Annual Sales$10,000.00 Price / Sales3,033.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book8.00Miscellaneous Outstanding Shares18,960,000Free Float17,749,000Market Cap$30.34 million OptionableNot Optionable Beta0.65 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Eugene Williams (Age 65)Co-Founder & Chairman Comp: $275kMr. Neil K. Warma M.B.A. (Age 61)President, Interim CEO, Principal Executive Officer & Director Comp: $40kDr. Neil R. Cashman M.D. (Age 72)Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director Comp: $359.66kMr. Gavin T. Malenfant (Age 60)Chief Operating Officer Comp: $416.73kMr. Daniel E. Geffken M.B.A. (Age 67)Chief Financial Officer Comp: $88.75kDr. Johanne Kaplan Ph.D. (Age 64)Chief Development Officer Comp: $259.46kDr. Ernest D. Bush Ph.D.Head of Pharmacology/Toxicology & Senior ConsultantDr. David Wishart Ph.D.Chief Physics OfficerMr. Dennis Chen Ph.D.Head of Manufacturing & Senior ConsultantDr. Larry Douglas Altstiel M.D. (Age 74)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsCompugenNASDAQ:CGENProQR TherapeuticsNASDAQ:PRQR10X Capital Venture Acquisition Corp. IIINYSE:VCXBIncannex HealthcareNASDAQ:IXHLAtyr PHARMANASDAQ:ATYRView All Competitors PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? ProMIS Neurosciences' stock was trading at $1.15 at the start of the year. Since then, PMN shares have increased by 39.1% and is now trading at $1.60. View the best growth stocks for 2024 here. How were ProMIS Neurosciences' earnings last quarter? ProMIS Neurosciences, Inc. (NASDAQ:PMN) posted its earnings results on Tuesday, May, 14th. The company reported ($0.19) earnings per share for the quarter. How do I buy shares of ProMIS Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
